Skip to main content
main-content
Erschienen in: CardioVasc 4/2022

22.09.2022 | Myokarditis | Zertifizierte Fortbildung

Während und nach Krebstherapie sind Verlaufskontrollen obligat

Kardiologische Langzeitfolgen nach Malignom-Behandlung

verfasst von: Dr. med. Lars Michel, Prof. Dr. med. Tienush Rassaf

Erschienen in: CardioVasc | Ausgabe 4/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Die kardiovaskuläre Morbidität und Mortalität von Krebspatienten kann durch eine sinnvolle Risikoabschätzung, eine präzise Diagnostik sowie geeignete Maßnahmen zur Überwachung von Spätkomplikationen signifikant gesenkt werden. Dieser Beitrag gibt einen Überblick über die onkologischen Therapien sowie ihre mög- lichen kardiovaskulären Nebenwirkungen, um eine bestmögliche Behandlung der Patienten zu gewährleisten. …
Literatur
1.
Zurück zum Zitat Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges, new opportunities. Herz. 2020;45:619-25 Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges, new opportunities. Herz. 2020;45:619-25
2.
Zurück zum Zitat Rassaf T, Totzeck M, Backs J et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020;109:1197-222 Rassaf T, Totzeck M, Backs J et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020;109:1197-222
3.
Zurück zum Zitat Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity J Thorac Dis. 2018;10:S4282-95 Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity J Thorac Dis. 2018;10:S4282-95
4.
Zurück zum Zitat Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2019;37:2768-801 Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2019;37:2768-801
5.
Zurück zum Zitat Totzeck M, Schuler M, Stuschke M et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163-75 Totzeck M, Schuler M, Stuschke M et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163-75
6.
Zurück zum Zitat Michel L, Mincu RI, Mahabadi AA et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22:350-61 Michel L, Mincu RI, Mahabadi AA et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22:350-61
7.
Zurück zum Zitat Cardinale D, Lacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26 Cardinale D, Lacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26
8.
Zurück zum Zitat Totzeck M, Mincu RI, Heusch G et al. Heart failure from cancer therapy: can we prevent it? ESC Heart Fail. 2019;6:856-62 Totzeck M, Mincu RI, Heusch G et al. Heart failure from cancer therapy: can we prevent it? ESC Heart Fail. 2019;6:856-62
9.
Zurück zum Zitat McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726 McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726
10.
Zurück zum Zitat Mrotzek SM, Rassaf T, Totzeck M. Cardiovascular Damage Associated With Chest Irradiation. Front Cardiovasc Med. 2020;7:41 Mrotzek SM, Rassaf T, Totzeck M. Cardiovascular Damage Associated With Chest Irradiation. Front Cardiovasc Med. 2020;7:41
11.
Zurück zum Zitat Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021;10:e021686 Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021;10:e021686
12.
Zurück zum Zitat Tuohinen SS, Skyttä T, Huhtala H et al. 3-Year Follow-Up of Radiation-Associated Changes in Diastolic Function by Speckle Tracking Echocardiography. JACC: CardioOncology. 2021;3:277-89 Tuohinen SS, Skyttä T, Huhtala H et al. 3-Year Follow-Up of Radiation-Associated Changes in Diastolic Function by Speckle Tracking Echocardiography. JACC: CardioOncology. 2021;3:277-89
13.
Zurück zum Zitat Cao L, Cai G, Chang C et al. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab. Oncologist. 2015;20:605-14 Cao L, Cai G, Chang C et al. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab. Oncologist. 2015;20:605-14
14.
Zurück zum Zitat Taylor C, Correa C, Duane FK et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35:1641-49 Taylor C, Correa C, Duane FK et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35:1641-49
15.
Zurück zum Zitat Haddy N, Diallo S, El-Fayech C et al. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study. Circulation. 2016;133:31-8 Haddy N, Diallo S, El-Fayech C et al. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study. Circulation. 2016;133:31-8
16.
Zurück zum Zitat Goel S, Liu J, Guo H et al. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail. 2019;7:795-804 Goel S, Liu J, Guo H et al. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail. 2019;7:795-804
17.
Zurück zum Zitat Dempsey N, Rosenthal A, Dabas N et al. Breast Cancer Res Treat. 2021;188:21-36 Dempsey N, Rosenthal A, Dabas N et al. Breast Cancer Res Treat. 2021;188:21-36
18.
Zurück zum Zitat Totzeck M, Mincu Raluca I, Rassaf T. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. J Am Heart Assoc. 2017;6:e006278 Totzeck M, Mincu Raluca I, Rassaf T. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. J Am Heart Assoc. 2017;6:e006278
19.
Zurück zum Zitat D'Souza M, Nielsen D, Svane IM et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42:1621-31 D'Souza M, Nielsen D, Svane IM et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42:1621-31
20.
Zurück zum Zitat Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420 Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420
21.
Zurück zum Zitat Lyon AR, Yousaf N, Battisti NML et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447-58 Lyon AR, Yousaf N, Battisti NML et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447-58
22.
Zurück zum Zitat Mahmood SS, Fradley MG, Cohen JV et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71:1755-64 Mahmood SS, Fradley MG, Cohen JV et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71:1755-64
23.
Zurück zum Zitat Awadalla M, Mahmood SS, Groarke JD et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75:467-78 Awadalla M, Mahmood SS, Groarke JD et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75:467-78
24.
Zurück zum Zitat Drobni ZD, Alvi RM, Taron J et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142:2299-311 Drobni ZD, Alvi RM, Taron J et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142:2299-311
25.
Zurück zum Zitat Michel L, Totzeck M, Lehmann L, Finke D. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz. 2020;45:645-51 Michel L, Totzeck M, Lehmann L, Finke D. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz. 2020;45:645-51
26.
Zurück zum Zitat Ghosh AK, Chen DH, Guha A et al. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2:97-109 Ghosh AK, Chen DH, Guha A et al. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2:97-109
Metadaten
Titel
Während und nach Krebstherapie sind Verlaufskontrollen obligat
Kardiologische Langzeitfolgen nach Malignom-Behandlung
verfasst von
Dr. med. Lars Michel
Prof. Dr. med. Tienush Rassaf
Publikationsdatum
22.09.2022
Verlag
Springer Medizin
Erschienen in
CardioVasc / Ausgabe 4/2022
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-022-3704-8